| Use of Psychologist-administered Cognitive Behavioral Therapy (CBT) or Self-administered CBT for the Treatment of Anxiety and/or Depression in Inflammatory Bowel Disease (IBD) (NCT05377840) | Yale University | 2022-07-05 |
| A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis (NCT05377580) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-07-01 |
| NORDTREAT Prospective Study on Inflammatory Bowel Disease (NCT05414578) | University of Southern Denmark | 2022-02-07 |
| IBD Biomarker Discovery and Validation Platform (NCT07686406) | Sixth Affiliated Hospital, Sun Yat-sen University | 2022-01-01 |
| Education Intervention on Vaccination Adherence Among Inflammatory Bowel Disease (IBD) Patients (NCT04672161) | Weill Medical College of Cornell University | 2021-02-04 |
| Research for the Precision Medicine in the Treatment of Inflammatory Bowel Disease (NCT07166588) | Seoul National University Hospital | 2021-01-20 |
| An Exploration of the Relationship Between Serum Cytokine Levels and the Clinical Efficacy of Vedolizumab (NCT06855862) | Second Affiliated Hospital of Wenzhou Medical University | 2020-11-05 |
| TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study (NCT03920254) | Theravance Biopharma | 2020-07-23 |
| The Role of CALLY and HAALP in Ulcerative Colitis (NCT07236333) | Ataturk University | 2020-06-01 |
| A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease (NCT04254783) | AbbVie | 2020-05-27 |
| The Association Between Interleukin-7 Receptor Gene Polymorphism and the Risk of Ulcerative Colitis (NCT07398586) | Second Affiliated Hospital of Wenzhou Medical University | 2020-01-01 |
| Comparative Outcomes of Ulcerative Colitis Patients With Mayo Endoscopic Score 1 and Histologic Activity Versus Mayo Endoscopic Score 2 (NCT07188727) | IRCCS San Raffaele | 2019-09-01 |
| A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease (NCT04031469) | ProgenaBiome | 2019-07-11 |
| A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy (NCT03695185) | AbbVie | 2019-03-26 |
| Efficacy & Safety of TD-1473 in Ulcerative Colitis (NCT03758443) | Theravance Biopharma | 2019-03-11 |
| A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis (NCT03653026) | AbbVie | 2018-12-06 |
| Chronic Inflammatory Disease, Lifestyle and Risk of Disease (NCT03456206) | University of Southern Denmark | 2018-11-10 |
| A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis (NCT03398135) | AbbVie | 2018-08-28 |
| Adipose Mesenchymal Stem Cells (AMSC) for Treatment of Ulcerative Colitis (NCT03609905) | Liaocheng People's Hospital | 2018-07-01 |
| A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis (NCT03398148) | AbbVie | 2018-03-07 |
| Impact of BAFF Gene Polymorphisms on the Risk of Ulcerative Colitis and the Efficacy of Vedolizumab. (NCT07564895) | Second Affiliated Hospital of Wenzhou Medical University | 2018-03-01 |
| Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease (NCT03801928) | Pfizer | 2018-02-23 |
| Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service (NCT03223012) | AbbVie | 2017-11-15 |
| A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) (NCT03006068) | AbbVie | 2017-01-31 |
| A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC) (NCT02819635) | AbbVie | 2016-09-26 |
| Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis (NCT02345733) | Prof. Arie Levine | 2015-09-01 |
| Use of the Ulcerative Colitis Diet for Induction of Remission (NCT02217722) | Prof. Arie Levine | 2014-10-01 |
| A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma (NCT02087878) | AbbVie | 2014-03-31 |
| Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis (NCT02065622) | AbbVie | 2014-03-27 |
| Early Serum Infliximab Levels in Severe Ulcerative Colitis. (NCT01971814) | University of California, San Francisco | 2013-11-01 |
| A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) (NCT01848561) | AbbVie | 2013-04-29 |
| Utilization of NBi in Assessing Luminal INflammaion in IBD (UNBLIND) (NCT02049775) | The Leeds Teaching Hospitals NHS Trust | 2013-04-01 |
| Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis D (NCT01877577) | University of California, San Francisco | 2012-04-01 |
| Anal Human Papillomavirus in Inflammatory Bowel Disease Study (NCT01364896) | University of Pittsburgh | 2011-06-01 |
| Expanded Access to Risankizumab (NCT03914261) | AbbVie | |